A study of births in women exposed to dolutegravir around the time of conception has confirmed that infants exposed to dolutegravir do not have an increased risk of neural tube defects.
The study authors say that their study suggests that in a setting where food is supplemented with folic acid, infants exposed to dolutegravir around the time of conception of in early pregnancy do not show an increased risk of neural tube defects such as spina bifida.
But the study did find a slightly increased risk of pregnancy loss in all women with HIV who were taking antiretroviral treatment around the time of conception.
Read the full story at Aidsmap.
SEE ALSO:
Source : Aidsmap
Related HIV and Co-Infections News
-
UNICEF: Despite progress, adolescent girls continue to bear the brunt of the HIV epidemic with 98,000 new infections in 2022
-
Menopause may affect atherosclerosis risk differently in people with HIV, reports US study
-
Innovative HIV prevention product for women that promotes choice – dapivirine vaginal ring – gains momentum across Africa
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.